Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  sargramostim
Find trials that include:  Any drugs shown
Results 1-25 of 34 for your search:
Start Over
Peripheral Blood Stem Cell Transplant in Treating Patients with Acute Myeloid Leukemia
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 70 and under
Trial IDs: MT2006-13, NCI-2010-02369, 0607M89052, UMN-MT2006-13, NCT00630565
Nivolumab and Ipilimumab with or without Sargramostim in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EA6141, NCI-2014-02674, NCT02339571
Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 75
Trial IDs: 10-000062, NCI-2013-00645, 10-001674, 11-002177, NCT01826864
Humanized Monoclonal Antibody 3F8 and Sargramostim in Treating Patients with Relapsed or Refractory High-Risk Neuroblastoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 1
Trial IDs: 12-230, NCI-2013-00007, NCT01757626
OKT3/Humanized 3F8 Bispecific Antibody-Activated T Lymphocytes, Aldesleukin, and Sargramostim in Treating Younger Patients with GD2-Positive Metastatic, Recurrent or Refractory Solid Tumors
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 13 months to 29 years
Trial IDs: 2013-171, NCI-2014-01149, 1403012875, NCT02173093
Bispecific Antibody Armed Activated T-cells with Aldesleukin and Sargramostim in Treating Patients with Locally Advanced or Metastatic Pancreatic Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-100, NCI-2015-01942, 1510014428, NCT02620865
Vaccine Therapy and Sargramostim With or Without Imiquimod in Treating Patients With Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 07-380, NCI-2014-00281, NCT00799110
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
Status: Active
Phase: Phase II
Type: Prevention
Age: 18 and over
Trial IDs: 368255, NCI-2015-00026, 1137008 / 20130058, NCT01570036
Azacitidine and Sargramostim as Maintenance Therapy in Treating Patients with Poor-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome That Have Undergone Stem Cell Transplant or Received Cytarabine-Based Chemotherapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 6 months and older
Trial IDs: J1240, NCI-2014-01349, NA_00072223, NA_00072223_AM00039689, NCT01700673
Irinotecan Hydrochloride and Temozolomide with Temsirolimus or Dinutuximab in Treating Younger Patients with Refractory or Relapsed Neuroblastoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Children
Trial IDs: ANBL1221, NCI-2012-03125, CDR0000745188, COG-ANBL1221, PANBL1221_A08PAMDREVW01, NCT01767194
ERC1671/GM-CSF/Cyclophosphamide in Treating Patients with Relapsed Glioblastoma Multiforme
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ERC1671-H02, NCI-2014-00737, 11922, ERC1671, UCI 13-14, NCT01903330
Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Status: Active
Phase: Phase II
Type: Prevention
Age: 18 and over
Trial IDs: 2014-0443, NCI-2015-00033, NCT02297698
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients with Newly Diagnosed Glioblastoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 259614, NCI-2015-00694, NCT02455557
Dinutuximab in Combination with Sargramostim in Treating Patients with Recurrent Osteosarcoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 29 and under
Trial IDs: AOST1421, NCI-2015-01001, NCT02484443
Humanized Monoclonal Antibody 3F8 and Sargramostim in Treating Patients with Recurrent Osteosarcoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 2 to 40
Trial IDs: 15-096, NCI-2015-01423, NCT02502786
Abbreviated Mycophenolate Mofetil and Sargramostim after Stem Cell Transplant in Treating Patients with High Risk or Recurrent Hematological Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 74
Trial IDs: MCC-14-10739, NCI-2015-01889, NCT02593123
Nelipepimut-S plus GM-CSF Vaccine Therapy in Treating Patients with Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2016-0164, NCI-2015-02189, N01-CN-2012-00034, MDA2014-04-02, NCT02636582
Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: FRV-002, NCI-2016-00538, NCT02593227
Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: BMTCTN1401, NCI-2016-00911, U01HL069294, NCT02728102
Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GL0817-01, NCI-2016-01681, 2016-001256-22, NCT02873819
Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: FRV-004, NCI-2016-01896, NCT02978222
Humanized Monoclonal Antibody 3F8, Sargramostim, and Isotretinoin in Treating Patients with High-Risk Neuroblastoma in First Remission
Status: Active
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 16-1643, NCI-2017-00121, NCT03033303
Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim, and Cyclophosphamide in Treating Patients with Triple Negative Breast Cancer
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: RU011501I, NCI-2016-01878, NCT03012100
Donor Natural Killer Cell Infusion after Autologous CD133+ Selected Stem Cell Transplant in Treating Younger Patients with High Risk Solid Tumors or Lymphomas
Status: Active
Phase: Phase I
Type: Treatment
Age: 21 and under
Trial IDs: ASCIST, NCI-2014-00275, NCT02130869
Start Over